デフォルト表紙
市場調査レポート
商品コード
1518671

放射線皮膚炎市場レポート:製品、流通チャネル、地域別、2024年~2032年

Radiodermatitis Market Report by Product (Topical, Oral, Dressings), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region 2024-2032


出版日
発行
IMARC
ページ情報
英文 135 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
放射線皮膚炎市場レポート:製品、流通チャネル、地域別、2024年~2032年
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射線皮膚炎の世界市場規模は2023年に4億9,950万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに6億6,030万米ドルに達し、2024年から2032年の間に3.06%の成長率(CAGR)を示すと予測しています。

放射線皮膚炎とは、がんの治療に使用される放射線療法によって引き起こされる皮膚症状のことです。一般に、乳がん、肺がん、皮膚がん、頸部がん、頭部がん、肛門周囲がんなど、皮膚が標的領域の一部となっているがん患者のがん治療中やインターベンショナル・ラジオロジー後に副作用として発生します。放射線皮膚炎を治療するために一般的に使用される製品には、局所抗生物質、コルチコステロイド、親水性クリーム、ハイドロゲルおよびハイドロコロイド包帯、シリコン被覆包帯、銀箔包帯、経口鎮痛剤、抗炎症剤などがあります。近年、放射線皮膚炎治療は、不快感を軽減し、痛みを最小限に抑え、継続的な治療の中断を防ぐと同時に、患者の生活全体の質を向上させることから、支持を集めています。

放射線皮膚炎市場傾向:

がんの蔓延と治療オプションとしての放射線療法の採用増加は、市場成長を促進する主な要因です。これに加えて、世界の老年人口の増加と放射線治療の副作用に対処する必要性の高まりが、放射線皮膚炎治療の需要を増大させています。さらに、多くの政府機関や非政府機関が、利用可能な放射線皮膚炎治療・管理製品に関する認識を広めるために積極的な取り組みを行っています。このことは、ライフサイエンス分野で進行中の研究開発(R&D)活動への公的・民間投資の増加と相まって、市場の成長を促進しています。さらに、大手企業は製品ポートフォリオを拡大し競争力を高めるため、革新的な製品の開発に注力しています。さらに、臨床試験件数の増加、有利な政府政策、消費者の支出能力の増加、ヘルスケアインフラの改善、ジェネリック医薬品の容易な入手などが、市場の見通しを明るいものにしています。

本レポートで扱う主な質問

  • 2023年における世界の放射線皮膚炎市場の市場規模は?
  • 2024-2032年における世界の放射線皮膚炎市場の予想成長率は?
  • 世界の放射線皮膚炎市場に対するCOVID-19の影響は?
  • 世界の放射線皮膚炎市場を牽引する主要因は?
  • 世界の放射線皮膚炎市場の製品別内訳は?
  • 世界の放射線皮膚炎市場の主要地域は?
  • 世界の放射線皮膚炎市場の主要プレイヤー/企業は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の放射線皮膚炎市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:製品別

  • 外用
    • 市場動向
    • 主要セグメント
      • コルチコステロイド
      • 親水性クリーム
      • 抗生物質
      • その他
    • 市場予測
  • 経口
    • 市場動向
    • 市場予測
  • 被覆材
    • 市場動向
    • 主要セグメント
      • ハイドロゲルおよびハイドロコロイドドレッシング
      • 刺傷防止フィルム
      • 蜂蜜を染み込ませたガーゼ
      • シリコンコーティングドレッシング
      • その他
    • 市場予測

第7章 市場内訳:流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第8章 市場内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • 3M Company
    • Bausch Health Companies Inc.
    • Bayer AG
    • BMG PHARMA S.p.A.
    • Charles River Laboratories International Inc.
    • ConvaTec Group plc
    • Helsinn Healthcare SA
    • ICON plc
    • Integra LifeSciences
    • Molnlycke Health Care AB
    • Stratpharma AG
図表

List of Figures

  • Figure 1: Global: Radiodermatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Radiodermatitis Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Radiodermatitis Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Radiodermatitis Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Radiodermatitis Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Radiodermatitis (Topical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Radiodermatitis (Topical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Radiodermatitis (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Radiodermatitis (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Radiodermatitis (Dressings) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Radiodermatitis (Dressings) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Radiodermatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Radiodermatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Radiodermatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Radiodermatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Radiodermatitis (Online Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Radiodermatitis (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: North America: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: North America: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: United States: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: United States: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Canada: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Canada: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Asia-Pacific: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Asia-Pacific: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: China: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: China: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Japan: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Japan: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: India: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: India: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: South Korea: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: South Korea: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Australia: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Australia: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Indonesia: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Indonesia: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Others: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Others: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Europe: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Europe: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Germany: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Germany: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: France: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: France: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: United Kingdom: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: United Kingdom: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Italy: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Italy: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Spain: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Spain: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Russia: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Russia: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Others: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Others: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Latin America: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Latin America: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Brazil: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Brazil: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Mexico: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Mexico: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Middle East and Africa: Radiodermatitis Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Middle East and Africa: Radiodermatitis Market: Breakup by Country (in %), 2023
  • Figure 67: Middle East and Africa: Radiodermatitis Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Global: Radiodermatitis Industry: SWOT Analysis
  • Figure 69: Global: Radiodermatitis Industry: Value Chain Analysis
  • Figure 70: Global: Radiodermatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Radiodermatitis Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Radiodermatitis Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Radiodermatitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Radiodermatitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Radiodermatitis Market: Competitive Structure
  • Table 6: Global: Radiodermatitis Market: Key Players
目次
Product Code: SR112024A5638

The global radiodermatitis market size reached US$ 499.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 660.3 Million by 2032, exhibiting a growth rate (CAGR) of 3.06% during 2024-2032.

Radiodermatitis, or radiation dermatitis, refers to a skin condition caused due to radiation therapy used for the treatment of cancer. It generally occurs as a side effect during cancer treatment or after interventional radiology in patients with cancers of the breast, lungs, skin, neck, head or perineum region where the skin is part of the target field. Some of the commonly used products to treat radiodermatitis include topical antibiotics, corticosteroids, hydrophilic creams, hydrogel and hydrocolloid dressings, silicone-coated dressings, silver-leaf dressings, oral analgesics, and anti-inflammatory agents. In recent years, radiodermatitis treatment has gained traction as it helps reduce discomfort, minimize pain and prevent interruption in ongoing therapy while improving the overall quality of the patient's life.

Radiodermatitis Market Trends:

The widespread prevalence of cancer and the rising adoption of radiation therapy as a treatment option represent the primary factors driving the market growth. Besides this, the increasing geriatric population across the globe and the growing need to counter the adverse side effects of radiation therapy are augmenting the demand for radiodermatitis treatment. Additionally, numerous governing and non-governing agencies are taking favorable initiatives to spread awareness regarding the available radiodermatitis treatment and management products. This, in confluence with the rising public and private investments in the ongoing research and development (R&D) activities in the field of life sciences, is catalyzing the market growth. Furthermore, the leading players are focusing on developing innovative product variants to expand their product portfolio and gain a competitive edge. Moreover, the rising number of clinical trials, favorable government policies, increasing consumer expenditure capacities, improving healthcare infrastructure and easy availability of generic drugs are some of the other factors creating a positive market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global radiodermatitis market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and distribution channel.

Breakup by Product:

Topical

Corticosteroids

Hydrophilic Creams

Antibiotics

Others

Oral

Dressings

Hydrogel and Hydrocolloid Dressings

No Sting Barrier Film

Honey Impregnated Gauze

Silicone Coated Dressings

Others

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Bausch Health Companies Inc., Bayer AG, BMG PHARMA S.p.A., Charles River Laboratories International Inc., ConvaTec Group plc, Helsinn Healthcare SA, ICON plc, Integra LifeSciences, Molnlycke Health Care AB and Stratpharma AG.

Key Questions Answered in This Report

  • 1. What was the size of the global radiodermatitis market in 2023?
  • 2. What is the expected growth rate of the global radiodermatitis market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global radiodermatitis market?
  • 4. What are the key factors driving the global radiodermatitis market?
  • 5. What is the breakup of the global radiodermatitis market based on the product?
  • 6. What is the breakup of the global radiodermatitis market based on the distribution channel?
  • 7. What are the key regions in the global radiodermatitis market?
  • 8. Who are the key players/companies in the global radiodermatitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Radiodermatitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Topical
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Corticosteroids
      • 6.1.2.2 Hydrophilic Creams
      • 6.1.2.3 Antibiotics
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Oral
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Dressings
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Hydrogel and Hydrocolloid Dressings
      • 6.3.2.2 No Sting Barrier Film
      • 6.3.2.3 Honey Impregnated Gauze
      • 6.3.2.4 Silicone Coated Dressings
      • 6.3.2.5 Others
    • 6.3.3 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 3M Company
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Bausch Health Companies Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 BMG PHARMA S.p.A.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Charles River Laboratories International Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 ConvaTec Group plc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Helsinn Healthcare SA
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
    • 13.3.8 ICON plc
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Integra LifeSciences
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Molnlycke Health Care AB
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 SWOT Analysis
    • 13.3.11 Stratpharma AG
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio